Melodiol Global Health Limited

Health House Australia and Corporate Update

Melodiol Global Health Limited (ASX:ME1) (‘Melodiol’ or ‘the Company’) is pleased to advise that its wholly owned Australian subsidiary, Health House Australia, continues to make strong operational progress.


Highlights:

  • Health House Australia announces the planned launch of its medicinal cannabis clinic in Q2 of 2024
  • The group is also pleased to announce that it has added several new suppliers during Q1 of 2024
  • Health House Australia was a key contributor to Melodiol group FY 2023 revenues of $21.6m (an increase of 148% on FY 2022)
  • Health House Australia and Health House UK contributed $11.5m to group FY 23 revenues
  • Placement completed to fund working capital requirements
Over the past several months, Health House Australia has undertaken significant internal analysis and planning for the launch of its medicinal cannabis clinic. Health House Australia expects the Health House Wellness Clinic to be operational in Q2 of 2024 and views this activity as a key strategic objective. The operation of the Health House Wellness Clinic is expected to significantly extend Health House Australia’s value proposition to existing and prospective suppliers. The ability to attract and add new suppliers to the group’s portfolio is a significant driver of the group’s ability to grow revenues.

During Q1 of 2024, Health House Australia successfully added several new suppliers to its existing base. These include Botanitech, Chemovar, Endoca, Quantum, and MedTEC Pharma’s announcement of Health House Australia as its lead launch partner on the introduction of their Australian-grown flower and oil medicines, slated for Q2 of 2024. The continued addition of new suppliers to its portfolio is a core strategic objective of Health House Australia.

Management commentary:

CEO and Managing Director, Mr William Lay said: “Since being Australia’s first company to import medicinal cannabis in 2017, Health House Australia’s unwavering commitment to great service and integrity has led to it becoming one of the trusted names within the distribution of medical cannabis in Australia. I am very proud of our team for their hard work to remain a supplier of choice for existing relationships, and for continuing to expand the supplier base. Additionally, we are very excited about the launch of Health House’s medical cannabis clinic in Q2 of 2024, which will serve to further strengthen Health House Australia’s value proposition to existing and new suppliers.”

Placement:

The Company advises that it has received firm commitments to raise $796,000 (before costs) through the issue of approximately 180,090,498 new fully paid ordinary shares (‘Shares’) at an issue price of $0.00442 per Share (the ‘Placement’).

The Company will issue 101,357,466 shares today, representing $488,000 of the placement proceeds, with the remainder to be completed on a deferred settlement basis no later than 16 April 2024. Please refer to the Company’s Appendix 2A and Appendix 3B lodged today for further details on the placement.


Click here for the full ASX Release

This article includes content from Melodiol Global Health, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

ME1:AU
The Conversation (0)

Right Season is Unaware of Any Material Change

(TheNewswire)

Right Season Investments Corp.

May 28, 2025 TheNewswire - Vancouver, British Columbia Right Season Investments Corp. (TSXV: LITT ), (" Right Season " or the " Company "). At the request of the Canadian Investment Regulatory Organization, the Company wishes to confirm that its management is unaware of any material change in the Company's operations that would account for the recent increase in market activity.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less

CSE Bulletin: Delist - Better Plant Sciences Inc.

The common shares of Better Plant Sciences Inc. will be delisted from the CSE at market close today, May 27, 2025.

Better Plant Sciences is currently suspended. See Bulletin 2024-0121.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference

Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference

COMPASS Pathways Plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference at 10:30 am ET on May 20 th , 2025.

A live audio webcast of the presentation will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Glowing mushrooms with colorful graphs in the background on a dark surface.

US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025

When the US Food and Drug Administration (FDA) rejected Lykos Therapeutics’ new drug application for MDMA-assisted therapy last August, the initial disappointment cast a shadow over the psychedelics industry.

However, the sector is seeing a resurgence of optimism in 2025 on the back of various US developments.

“The psychedelic industry in 2025 will likely see significant advancements in clinical applications, particularly in treating PTSD, depression, and addiction, as research continues to validate their therapeutic potential,” Dr. Markus Ploesser, chief innovation officer at Open Mind Health, told Microdose in January.

Keep reading...Show less
Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights

Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights

Highlights:

  • 6-week top-line data from Part A of COMP005 phase 3 trial in treatment resistant depression on track for late June
  • Phase 3 COMP006 in TRD on track for 26-week data second half of 2026
  • Cash position of $260.1 million at March 31, 2025
  • Conference call on May 8 at 8:00 am ET (1:00 pm UK)

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

COMPASS Pathways Plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into a strategic collaboration with HealthPort, a multi-site comprehensive community health organization. HealthPort employs an integrated model centered around social determinants of health and this collaboration will help inform the potential delivery of COMP360 synthesized psilocybin treatment in underserved communities, if FDA approved. This agreement with HealthPort expands the set of collaborations that Compass has established representing a broad spectrum of settings where people living with treatment resistant depression (TRD) receive their care in the United States.

HealthPort offers an integrated model of care aimed at helping those with behavioral health conditions and people impacted by poverty, disability and trauma. HealthPort is an evidence-based practice supporting thirteen dimensions of social determinants of health, including the coordination of an integrated outpatient mental health and addictions health clinic. HealthPort has been operating facility, residential, and mobile based interventions of care in the lower Eastern Shore of Maryland for the past 45 years.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×